<code id='260E3AA16A'></code><style id='260E3AA16A'></style>
    • <acronym id='260E3AA16A'></acronym>
      <center id='260E3AA16A'><center id='260E3AA16A'><tfoot id='260E3AA16A'></tfoot></center><abbr id='260E3AA16A'><dir id='260E3AA16A'><tfoot id='260E3AA16A'></tfoot><noframes id='260E3AA16A'>

    • <optgroup id='260E3AA16A'><strike id='260E3AA16A'><sup id='260E3AA16A'></sup></strike><code id='260E3AA16A'></code></optgroup>
        1. <b id='260E3AA16A'><label id='260E3AA16A'><select id='260E3AA16A'><dt id='260E3AA16A'><span id='260E3AA16A'></span></dt></select></label></b><u id='260E3AA16A'></u>
          <i id='260E3AA16A'><strike id='260E3AA16A'><tt id='260E3AA16A'><pre id='260E3AA16A'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:554
          Adobe

          Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

          In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

          advertisement

          Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          What does generative AI mean for health care? We asked experts
          What does generative AI mean for health care? We asked experts

          MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

          read more
          Bristol Myers buys into radiopharmaceuticals with RayzeBio
          Bristol Myers buys into radiopharmaceuticals with RayzeBio

          CourtesyBristolMyersSquibbBristolMyersSquibbwillpay$4.1billionforRayzeBio,thecompaniessaidTuesday,bu

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Prime Medicine, Myeloid Therapeutics clash over genome

          AdobeThecloselywatchedgene-editingstartupPrimeMedicineisembroiledinamultimillion-dollardisputewithan